Advm Stock Insider Trading

Healthcare > Biotechnology

Buy ADVM

*Your capital is at risk

$4.36

+0 (+0%)

At Close: Mar 06, 2026

ADVM Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -77.06. In total, the insiders bought 1.26M and sold 2.94M ADVM shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-77.06
● Buy	1.26M shares
● Sell	2.94M shares
9% Buy Activity Moderate Positive Correlation
Sell Signal High Confidence Dec 09, 2025 Analysis Breakdown: Strongly supported by a very low Insider Power Score of -77.06. Partially supported by a positive historical correlation. Confidence increased due to high data reliability score of 100. Supported by overwhelming sell-side pressure (9% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Dec 09, 2025 Sell	Stock Option (Right to Buy) D-Return	Whitcup Scott M Director	Director	10 450 Value: $24.2K
Dec 09, 2025 Sell	Stock Option (Right to Buy) D-Return	Whitcup Scott M Director	Director	4 000 Value: $62.4K
Dec 09, 2025 Sell	Stock Option (Right to Buy) D-Return	Hong Soo Director	Director	10 450 Value: $24.2K
Dec 09, 2025 Sell	Stock Option (Right to Buy) D-Return	Hong Soo Director	Director	10 520 Value: $77.0K
Dec 09, 2025 Sell	Stock Option (Right to Buy) D-Return	Seyedkazemi Setareh Chief Development Officer	Officer	43 458 Value: $310.7K
Dec 09, 2025 Buy	Common Stock M-Exempt	Rubinstein Linda M Chief Financial Officer	C-Suite Officer	48 750 Value: $204.8K
Dec 09, 2025 Buy	Common Stock - Performance Stock Units A-Award	Rubinstein Linda M Chief Financial Officer	C-Suite Officer	42 000 Value: $183.1K
Dec 09, 2025 Sell	Common Stock - Restricted Stock Units U-Tender	Rubinstein Linda M Chief Financial Officer	C-Suite Officer	8 125 Value: $28.9K
Dec 09, 2025 Sell	Common Stock - Performance Stock Units U-Tender	Rubinstein Linda M Chief Financial Officer	C-Suite Officer	42 000 Value: $149.5K
Dec 09, 2025 Sell	Stock Option (Right to Buy) D-Return	Rubinstein Linda M Chief Financial Officer	C-Suite Officer	85 000 Value: $861.9K
Dec 09, 2025 Sell	Stock Option (Right to Buy) D-Return	Rubinstein Linda M Chief Financial Officer	C-Suite Officer	62 083 Value: $443.9K
Dec 09, 2025 Buy	Stock Option (Right to Buy) M-Exempt	Rubinstein Linda M Chief Financial Officer	C-Suite Officer	48 750 Value: $204.8K
Dec 09, 2025 Sell	Common Stock U-Tender	Rubinstein Linda M Chief Financial Officer	C-Suite Officer	61 150 Value: $217.7K
Dec 09, 2025 Sell	Stock Option (Right to Buy) D-Return	Hong Soo Director	Director	4 000 Value: $62.4K
Dec 09, 2025 Sell	Stock Option (Right to Buy) D-Return	Hong Soo Director	Director	8 000 Value: $108.0K
Dec 09, 2025 Sell	Stock Option (Right to Buy) D-Return	Whitcup Scott M Director	Director	10 520 Value: $77.0K
Dec 09, 2025 Sell	Stock Option (Right to Buy) D-Return	Whitcup Scott M Director	Director	3 000 Value: $769.2K
Dec 09, 2025 Sell	Stock Option (Right to Buy) D-Return	Tuckson Reed Vaughn Director	Director	4 000 Value: $39.6K
Dec 09, 2025 Sell	Stock Option (Right to Buy) D-Return	Tuckson Reed Vaughn Director	Director	10 450 Value: $24.2K
Dec 09, 2025 Sell	Stock Option (Right to Buy) D-Return	Svoronos Dawn Director	Director	4 000 Value: $148.0K
Dec 09, 2025 Sell	Stock Option (Right to Buy) D-Return	Svoronos Dawn Director	Director	10 520 Value: $77.0K
Dec 09, 2025 Sell	Stock Option (Right to Buy) D-Return	Scopa James Paul Director	Director	4 666 Value: $302.4K
Dec 09, 2025 Sell	Stock Option (Right to Buy) D-Return	Scopa James Paul Director	Director	4 000 Value: $62.4K
Dec 09, 2025 Sell	Common Stock U-Tender	Lupher, Jr. Mark L. Director	Director	13 000 Value: $46.3K
Dec 09, 2025 Sell	Stock Option (Right to Buy) D-Return	Lupher, Jr. Mark L. Director	Director	4 000 Value: $62.4K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT ADVM

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with U...

Read Full Profile Here